All News

Innovations such as the Apple iPhone HealthKit could help create a smooth transition throughout the patient journey all the way to the specialty pharmacy.

Teva has just unveiled the world's first integrated smart inhaler to the market.

An overview of scientific evidence supporting the HIV undetectable=untransmittable concept and implications for HIV prevention and treatment.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Clear differences in hepatitis C virus worldwide indicate the need to increase global understanding of the virus.

Overall, 3.1% of people in the United States sought treatment from their health care providers for flu-like illness during the week ended January 12, 2019.

Study suggests a survival benefit with ibrutinib compared with chemoimmunotherapy bendamustine plus rituximab in patients with chronic lymphocytic leukemia.

Officials with the FDA approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.

Can you solve the pharmaceutical mystery?

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

From 1990 to 2016, the rate of deaths due to adverse effects of medical treatment decreased 21.4% in the United States.

One lot of irbesartan and 7 lots of irbesartan and hydrochlorothiazide (HCTZ) combination tablets distributed by Solco Healthcare, a Prinston Pharmaceutical subsidiary are affected.

Students can set themselves apart during rotations, with these tips from a preceptor.

Officials with the FDA have approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.

Officials with the FDA today approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin.

Recommendations outline the efficacy of different types of therapies, dosing regimens, and routes for patients with mild-to-moderate ulcerative colitis.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Understanding the rate of hepatitis C infection is critical for making strategies to reduce the disease burden among specific populations.

Average total drug spending per hospital admission increased by 18.5% between FY2015 and FY2017.

Atezolizumab (Tecentriq) plus chemotherapy significantly extended survival in patients with metastatic non-squamous non-small cell lung cancer.

The target action date for the FDA’s decision on caplacizumab (Cablivi) is February 6, 2019.